Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24

Acta Pharmacologica Sinica

Volumn 30, Issue 4, 2009, Pages 467-477

  Wu, Yu Mei ^a   Zhang, Kang Jian ^a   Yue, Xue Tian ^a   Wang, Yi Qiang ^b   Yang, Yi ^a   Li, Gong Chu ^a   Li, Na ^a   Wang, Yi Gang ^a  

^a ZHEJIANG SCI TECH UNIVERSITY   (China)

^b Duchang People's Hospital   (China)

Author keywords

Apoptosis; Cisplatin; MDA 7 IL 24; Oncolytic adenovirus

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 24; ONCOLYTIC ADENOVIRUS; ANTINEOPLASTIC AGENT; INTERLEUKIN DERIVATIVE; INTERLEUKIN-24;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL STRUCTURE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; DRUG CONJUGATION; DRUG DOSE REDUCTION; DRUG POTENTIATION; EMBRYO; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NITROBLUE TETRAZOLIUM TEST; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIROTHERAPY; WESTERN BLOTTING; ADENOVIRUS; CELL LINE; DOSE RESPONSE; GENE THERAPY; GENETICS; MULTIMODALITY CANCER THERAPY; NEOPLASM; ONCOLYTIC VIROTHERAPY; PATHOLOGY;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE THERAPY; HUMANS; INTERLEUKINS; NEOPLASMS; ONCOLYTIC VIROTHERAPY;

EID: 65249112667     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.16     Document Type: Article

References (28)

1. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995; 11: 2477-86.
2. Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC, Fisher PB. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene 2002; 21: 708-18.
3. Su Z, Lebedeva IV, Gopalkrishnan RV, Goldstein NI, Stein CA, Reed JC, et al. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 2001; 98: 10332-7.
4. Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR, et al. mda-7/IL-24, a novel cancer selective apo-ptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ter 2003; 2: S23-S37.
5. Chada S, Mhashilkar AM, Liu Y, Nishikawa T, Bocangel D, Zheng M, et al. mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members. Cancer Gene Ter 2006; 13: 490-502.
6. Miyahara R, Banerjee S, Kawano K, Eferson C, Tsuda N, Miyahara Y, et al. Melanoma differentiation-associated gene-7 (mda-7)/ interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model. Cancer Gene Ter 2006; 13: 753-61.
7. Nishikawa T, Ramesh R, Munshi A, Chada S, Meyn RE. Adeno virus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograf tumors to radiation. Mol Ter 2004; 9: 818-28
8. Chada S, Nemunaitis J, Tong A, Zhang Y, Su D, Mhashilkar A, et al. A Phase I dose-escalation study of Ad-mda7 (INGN 241) in patients with advanced carcinoma. Cancer Gene Ther 2001; 8 (Suppl 2): S3.
9. Chada S, Cunningham C, Zhang Y, Su D, Mhashilkar A, Ekmekcioglu S, et al. INGN 241 (Ad-mda-7) induces widespread apoptosis and activates the immune system in patients with advanced cancer. Mol Ter 2003; 7: S446.
10. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efcacy. Cell Res 2003; 13: 481-99.
11. Liu XY, Qiu SB, Zou WG, Pei ZF, Gu JF, Luo CX, et al. Efective gene-virotherapy for complete eradication of tumor mediated by the combination of htrail (tnfsf10) and plasminogen k5. Mol Terapy 2005; 11: 531-41.
12. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ter 2005; 16: 845-58.
13. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-84.
14. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698-9.
15. Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M, et al Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomized factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15: 283-9.
16. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-40.
17. Pan QW, Liu BS, Liu J, Cai R, Wang YG, Qian C. Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRIL. Mol Cell Biochem 2007; 304: 315-23.
18. Pan QW, Zhong SY, Liu BS, Liu J, Cai R, Wang YG, et al. Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus. Acta Pharmacol Sin 2007; 28: 1996-2004.
19. Xiong J, Peng ZL, Tan X. Efects of adenoviral-mediated mda-7/ IL-24 gene infection on the growth and drug-resistance of drug-resistant ovarian cancer cell lines. Sichuan Da Xue Xue Bao Yi Xue Ban 2007; 38: 433-6. Chinese.
20. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. A controlled trial of ONYX-015, a replication-selective adenovirus, in combination with cisplatin and 5-FU in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-85.
21. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, et al. Genomic structure, chromosomal localization and expression profle of a novel melanoma diferen-tiation associated (mda-7) gene with cancer specifc growth suppress ing and apoptosis inducing properties. Oncogene 2001; 20: 7051-63.
22. Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell Res 2006; 16: 25-30.
23. Hajra KM, Tan L, Liu JR. Defective apoptosis underlies chemo-resistance in ovarian cancer. Adv Exp Med Biol 2008; 622: 197-208.
24. Uyama N, Hatano E, Maetani Y, Isoda H, Shibata T, Taura K, et al. Efcacy and toxicity of transcatheter arterial chemoembolization with cisplatin suspended in lipiodol for unresectable hepatocellular carcinoma. Gan To Kagaku Ryoho 2008; 35: 775-80.
25. Kirn D. Clinical research results with dl1520 (Onyx-015), a replica tion-selective adenovirus for the treatment of cancer: what have we learned? Gene Ter 2001; 8: 89-98.
26. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ter 2001; 1: 525-38.
27. Fillastre JP, Raguenez-Viote G. Cisplatin nephrotoxicity. Toxicol Let 1989; 46: 163-75.
28. Arany I, Safrstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460-4.